Physician profile
Angela Chen
NPI 1689824781
$3,709.29
in general payments reported to CMS, 2019-2025
24 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $603 · 2021: $685 · 2022: $274 · 2023: $152 · 2024: $982 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $789.12 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $784.24 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $528.19 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $462.42 | 2019-2025 | Repatha, Repatha, Krystexxa |
| Pfizer INC. | $302.24 | 2019-2024 | |
| Exact Sciences Corporation | $185.62 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $147.22 | 2020-2022 | |
| Amarin Pharma, INC. | $77.60 | 2019-2020 | |
| Astellas Pharma US INC | $64.03 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $62.57 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $33.22 | 2024-2025 | Contrave |
| Dynavax Technologies Corporation | $30.07 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $29.00 | 2019-2020 | |
| Abbvie INC. | $23.18 | 2022 | |
| Glaxosmithkline, LLC. | $22.90 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $22.61 | 2019 | |
| Dexcom, INC. | $22.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.59 | 2019 | |
| Abbott Laboratories | $21.26 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.80 | 2022 | |
| Sanofi Pasteur INC. | $17.91 | 2019 | |
| Gilead Sciences, INC. | $15.48 | 2022 | |
| Genentech USA, INC. | $14.22 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.